Chimerix to Announce Second Quarter 2018 Financial Results on August 8, 2018

DURHAM, N.C., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Chimerix CMRX, a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host a live conference call and audio webcast on Wednesday, August 8, 2018 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2018, and to provide a business overview.

To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 2976768. A live audio webcast of the call will also be available on the Investors' section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.

About Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and CMX521, the first clinical-stage direct-acting antiviral for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.

CONTACT:

Investor Relations:                            

Michelle LaSpaluto

(919) 972-7115

ir@chimerix.com 

or

Will O'Connor

Stern Investor Relations

Will@sternir.com 

212-362-1200

Media:

Becky Vonsiatsky

W2O Group

bvonsiatsky@w2ogroup.com 

413-478-2003